… study surrounds the drug rasagiline (brand name Azilect) from Teva Pharmaceuticals. You may remember that back in … benefit as a symptomatic therapy. The new clinical trial from Teva looked at 321 people with early PD, whose symptoms …

… Paddock (right) We’re expanding this series to hear from MJFF staff on their travels, past and future, as they … there are now, and how far they come for this—some from as far as Washington state and San Francisco. And with …

… says Nelson.  His plan is carried out by him, with input from his neurologist.  Coupled with the long term plan is … in positive frame of mind. Nelson also derives strength from  his friends (allies)  struggles against their …

… do we get the information we share on the experience of PD? From you, of course. This summer we asked our email and … to avoid or treat “off” episodes. Statistics like those from this survey of the patient community may influence …

… month the National Institutes of Health (NIH) hosted a workshop on clinical trial participation. The “ NIH Workshop on … workshop, and 210 viewed the live webcast. Representatives from the NIH, industry, patient advocacy organizations and … communication. MJFF: What was your biggest takeaway from the workshop? JR: The overarching message out of the …

… month MJFF welcomed more than 20 payers and policymakers from the neurology field to discuss what was important in … be interested to hear more about those kinds of experiences from the patient perspective.” We’ll continue to engage with …